Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Decoding the epitranscriptome: a new frontier for cancer therapy and drug resistance.

Autor: Tang, Lu^1,2 (AUTHOR), Tian, Hua^1,3 (AUTHOR), Min, Qi⁴ (AUTHOR), You, Huili^1,5 (AUTHOR), Yin, Mengshuang^1,5 (AUTHOR), Yang, Liqiong^1,5 (AUTHOR), Zhao, Yueshui^1,5 (AUTHOR), Wu, Xu^1,5 (AUTHOR), Li, Mingxing^1,5 (AUTHOR), Du, Fukuan^1,5 (AUTHOR), Chen, Yu^1,5 (AUTHOR), Deng, Shuai^1,5 (AUTHOR), Li, Xiaobing^1,5 (AUTHOR), Chen, Meijuan^1,5 (AUTHOR), Gu, Li¹ (AUTHOR), Sun, Yuhong¹ (AUTHOR), Xiao, Zhangang^1,5 (AUTHOR) zhangangxiao@swmu.edu.cn, Li, Wanping^1,5 (AUTHOR) 675832860@qq.com, Shen, Jing^1,5 (AUTHOR) jingshen@swmu.edu.cn

Publikováno v: Cell Communication & Signaling. 10/21/2024, Vol. 22 Issue 1, p1-35. 35p.

The YTH domain‐containing protein family: Emerging players in immunomodulation and tumour immunotherapy targets.

Autor: Li, Fenghe¹ (AUTHOR), Zeng, Chong² (AUTHOR), Liu, Jie³ (AUTHOR), Wang, Lei⁴ (AUTHOR), Yuan, Xiaorui¹ (AUTHOR), Yuan, Li⁵ (AUTHOR), Xia, Xiaomeng¹ (AUTHOR) xiaxiaomeng@csu.edu.cn, Huang, Wei^6,7,8 (AUTHOR) weihuang@csu.edu.cn

Publikováno v: Clinical & Translational Medicine. Aug2024, Vol. 14 Issue 8, p1-31. 31p.

Feasibility of prolonged use of interferon-alpha in metastatic kidney carcinoma: a phase II study

Autor: M, Kankuri, T T, Pelliniemi, S, Pyrhönen, V, Nikkanen, H, Helenius, E, Salminen

Publikováno v: Cancer. 92(4)

Interferon-alpha has proven effective in the treatment of metastatic renal cell carcinoma. However, the optimal schedule has not yet been determined. The authors have studied the efficacy and toxicity of prolonged use interferon-alpha2a (IFN-alpha) i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::bb2892fda6e47eb8d950fa220918741c
https://pubmed.ncbi.nlm.nih.gov/11550145